Pharmaceutical Talks

100 million doses to be produced by September:
AstraZeneca, the official partner for the coronavirus vaccine candidate fro Oxford, for the production and marketing of the vaccine has begun to produce AZD1222 jab, developed by the Oxford University, in UK, India, Switzerland, and Norway. The vaccine is under the human trials phase, but if successful, the company hopes to have millions of doses ready in the next few months. The company has reportedly signed a deal with the UK to produce 100 million doses, if the vaccine is successful in human trials and is expected to produce 2 billion doses worldwide, by mid-2021.